首页> 外文期刊>The Journal of Urology >Safety and efficacy outcome of mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment.
【24h】

Safety and efficacy outcome of mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment.

机译:辅导员alpha-1充气式阴茎假体植入治疗阳imp的安全性和有效性。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: We investigated safety and efficacy outcome pertaining to the Mentor Alpha-1, 3-piece inflatable penile prosthesis for impotence treatment. MATERIALS AND METHODS: A 2-phase, multi-institutional, large scale retrospective study, with independently analyzed medical record (phase I) and questionnaire (phase II) data from consecutive eligible patients of 7 physician investigators was performed from March to October 1993. RESULTS: In phase I there were no morbidities of any type in 394 of the 434 patients (90.8%) (mean age 61 years, range 24 to 88) who underwent Alpha-1 implantation (mean followup 22.2 months, range 0.67 to 44.5). The risk of prosthesis malfunction (fluid leak and auto-inflation) was 2.5%. No cylinder aneurysms were reported. A total of 93.1% of Alpha-1 devices was free from explantation (4.4%) or revision surgery (2.5%) for approximately 2 years from the original implant date. Kaplan-Meier actuarial analyses revealed that cumulative survival of the Alpha-1 prostheses at 12, 24 and36 months was 98 +/- 1%, 93 +/- 2% and 85 +/- 7% until device malfunction, and 91 +/- 2% 83 +/- 4% and 75 +/- 7% until surgical intervention (revision or explantation). In phase II 89% of the men claimed fulfilled expectations with the Alpha-1 prosthesis as impotence treatment. Satisfaction responses 80% or greater were noted with regard to intercourse ability and confidence, and device rigidity and function. Implantation did not result in greater than 80% satisfaction in partner relationships or feelings (as judged by the patient), social or work confidence, or intercourse frequency. Factors adversely affecting satisfaction included partner feelings of dissatisfaction (as judged by the patient), specific physician investigators and need for explantation/revision surgery. CONCLUSIONS: In 1 of the largest multi-institutional implant outcome studies thus far performed, safety and efficacy data concerning the Alpha-1 contemporary inflatable device were found markedly improved over earlier inflatable prostheses and now compare favorably with historical data from noninflatable rod type devices.
机译:目的:我们调查了有关用于阳imp治疗的三件式充气阴茎假体Mentor Alpha-1的安全性和有效性结果。材料与方法:从1993年3月至10月,进行了一项2阶段,多机构,大规模回顾性研究,该研究具有独立分析的病历(I期)和问卷(II期)数据,来自7位医师调查员的连续合格患者。结果:在第一阶段,接受Alpha-1植入的434例患者(平均年龄61岁,范围从24至88岁)中的394例(90.8%)(平均随访22.2个月,范围从0.67至44.5)中,没有任何类型的发病率。 。假体故障(流体泄漏和自动充气)的风险为2.5%。没有圆柱状动脉瘤的报道。从原始植入日期算起大约2年内,总共93.1%的Alpha-1设备没有进行外植(4.4%)或翻修手术(2.5%)。 Kaplan-Meier精算分析表明,直到装置出现故障,Alpha-1假体在12、24和36个月的累积存活率分别为98 +/- 1%,93 +/- 2%和85 +/- 7%,以及91 + / -2%83 +/- 4%和75 +/- 7%,直到进行外科手术(翻修或外植)。在第二阶段中,有89%的男性声称满足了使用Alpha-1假体作为阳fulfill治疗的期望。在性交能力和自信心以及器械的刚度和功能方面,满意度反应达到80%或更高。植入对伴侣关系或感觉(由患者判断),社交或工作信心或性交频率的满意度不超过80%。影响满意度的因素包括伴侣的不满意感(由患者判断),特定的医师调查人员以及需要进行植体/翻修手术。结论:在迄今为止进行的最大的多机构植入物结果研究中,一项研究发现,与早期可充气假体相比,有关Alpha-1当代可充气装置的安全性和有效性数据得到了显着改善,并且现在可与非可充气杆式装置的历史数据进行比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号